SI2024375T1 - S ciklopropilom zliti indolobenzazepin hcv ns5b inhibitorji - Google Patents

S ciklopropilom zliti indolobenzazepin hcv ns5b inhibitorji

Info

Publication number: SI2024375T1
Authority: SI; Slovenia
Prior art keywords: hcv ns5b; ns5b inhibitors; cyclopropyl fused; fused indolobenzazepine; indolobenzazepine hcv
Prior art date: 2006-05-17

Application number

SI200730612T

Other languages

English (en)

Inventor

John A Bender

Min Ding

Robert G Gentles

Piyasena Hewawasam

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-05-17

Filing date

2007-05-04

Publication date

2011-10-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38512732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2024375(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-05-04 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2011-10-28 Publication of SI2024375T1 publication Critical patent/SI2024375T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

SI200730612T 2006-05-17 2007-05-04 S ciklopropilom zliti indolobenzazepin hcv ns5b inhibitorji SI2024375T1 (sl)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US80112506P	2006-05-17	2006-05-17
US80200506P	2006-05-19	2006-05-19
US85208406P	2006-10-16	2006-10-16
US89475707P	2007-03-14	2007-03-14
PCT/US2007/068209 WO2007136982A1 (en)	2006-05-17	2007-05-04	Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
EP07761873A EP2024375B1 (en)	2006-05-17	2007-05-04	Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors

Publications (1)

Publication Number	Publication Date
SI2024375T1 true SI2024375T1 (sl)	2011-10-28

Family

ID=38512732

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI200730612T SI2024375T1 (sl)	2006-05-17	2007-05-04	S ciklopropilom zliti indolobenzazepin hcv ns5b inhibitorji

Country Status (24)

Country	Link
US (1)	US7456166B2 (sl)
EP (1)	EP2024375B1 (sl)
JP (1)	JP5284952B2 (sl)
KR (1)	KR101417145B1 (sl)
AR (1)	AR061008A1 (sl)
AT (1)	ATE501156T1 (sl)
AU (1)	AU2007253998B2 (sl)
BR (1)	BRPI0711821A2 (sl)
CA (1)	CA2651690C (sl)
CY (1)	CY1111526T1 (sl)
DE (1)	DE602007013036D1 (sl)
DK (1)	DK2024375T3 (sl)
EA (1)	EA015286B1 (sl)
HR (1)	HRP20110194T1 (sl)
IL (1)	IL195025A (sl)
MX (1)	MX2008014435A (sl)
NO (1)	NO341663B1 (sl)
NZ (1)	NZ572555A (sl)
PE (1)	PE20080070A1 (sl)
PL (1)	PL2024375T3 (sl)
SI (1)	SI2024375T1 (sl)
TW (1)	TWI401244B (sl)
WO (1)	WO2007136982A1 (sl)
ZA (1)	ZA200809548B (sl)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1688420A4 (en) *	2003-11-19	2008-10-22	Japan Tobacco Inc	5-5 LOW-CONDENSED HETEROCYCLIC COMPOUND AND THEIR USE AS HCV POLYMERASE INHIBITOR
US20070049593A1 (en)	2004-02-24	2007-03-01	Japan Tobacco Inc.	Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en)	2004-11-12	2010-02-09	Japan Tobacco Inc.	Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7521443B2 (en) *	2006-05-17	2009-04-21	Bristol-Myers Squibb Company	Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
JP5205370B2 (ja) *	2006-05-25	2013-06-05	ブリストル−マイヤーズスクイブカンパニー	シクロプロピル縮合インドロベンゾアゼピンｈｃｖｎｓ５ｂ阻害剤
US7541351B2 (en) *	2007-01-11	2009-06-02	Bristol-Myers Squibb Company	Compounds for the treatment of hepatitis C
US7541352B2 (en) *	2007-02-02	2009-06-02	Bristol-Myers Squibb Company	Compounds for the treatment of hepatitis C
US7517872B2 (en) *	2007-02-22	2009-04-14	Bristol-Myers Squibb Company	Compounds for the treatment of hepatitis C
US7998951B2 (en) *	2007-03-05	2011-08-16	Bristol-Myers Squibb Company	HCV NS5B inhibitors
JP5211078B2 (ja)	2007-03-13	2013-06-12	ブリストル−マイヤーズスクイブカンパニー	シクロプロピル縮合インドロベンズアゼピンｈｃｖｎｓ５ｂ阻害剤
US7541353B2 (en) *	2007-03-14	2009-06-02	Bristol-Myers Squibb Company	Compounds for the treatment of hepatitis C
US7521444B2 (en) *	2007-03-14	2009-04-21	Bristol-Myers Squibb Company	Compounds for the treatment of hepatitis C
US7547690B2 (en) *	2007-03-14	2009-06-16	Bristol-Myers Squibb Company	Compounds for the treatment of Hepatitis C
US7538102B2 (en) *	2007-03-14	2009-05-26	Bristol-Myers Squibb Company	Compounds for the treatment of Hepatitis C
US7538103B2 (en) *	2007-03-15	2009-05-26	Bristol-Myers Squibb Company	Compounds for the treatment of hepatitis C
CN102872461A (zh)	2007-05-04	2013-01-16	弗特克斯药品有限公司	用于治疗hcv感染的组合治疗
US8143243B2 (en) *	2007-08-09	2012-03-27	Bristol-Myers Squibb Company	Compounds for the treatment of hepatitis C
US7642251B2 (en) *	2007-08-09	2010-01-05	Bristol-Myers Squibb Company	Compounds for the treatment of hepatitis C
US7652004B2 (en) *	2007-08-09	2010-01-26	Bristol-Myers Squibb Company	Compounds for the treatment of hepatitis C
ATE533771T1 (de) *	2007-11-20	2011-12-15	Bristol Myers Squibb Co	Cyclopropylkondensierte indolobenzazepine als hcv-ns5b-inhibitoren
US8124601B2 (en) *	2007-11-21	2012-02-28	Bristol-Myers Squibb Company	Compounds for the treatment of Hepatitis C
US8129367B2 (en) *	2007-11-21	2012-03-06	Bristol-Myers Squibb Company	Compounds for the treatment of Hepatitis C
MX2010006313A (es)	2007-12-19	2010-06-25	Boehringer Ingelheim Int	Inhibidores de la polimerasa virica.
PL2238142T3 (pl)	2007-12-24	2012-11-30	Janssen R&D Ireland	Makrocykliczne indole jako inhibitory wirusa zapalenia wątroby typu C
ES2416062T3 (es) *	2008-03-27	2013-07-30	Bristol-Myers Squibb Company	Inhibidores de NS5B del VHC de indolobenzadiazepina condensados con pirrolidina
JP2011515496A (ja) *	2008-03-27	2011-05-19	ブリストル−マイヤーズスクイブカンパニー	ジオキソランおよびジオキソラノン縮合インドロベンザジアゼピンｈｃｖｎｓ５ｂ阻害剤
AU2009228337A1 (en) *	2008-03-27	2009-10-01	Bristol-Myers Squibb Company	Compounds for the treatment of hepatitis C
US8133884B2 (en) *	2008-05-06	2012-03-13	Bristol-Myers Squibb Company	Compounds for the treatment of hepatitis C
TWI454476B (zh) *	2008-07-08	2014-10-01	Tibotec Pharm Ltd	用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
UY32099A (es)	2008-09-11	2010-04-30	Enanta Pharm Inc	Inhibidores macrocíclicos de serina proteasas de hepatitis c
JP2012514605A (ja)	2009-01-07	2012-06-28	サイネクシス，インコーポレーテッド	Ｈｃｖおよびｈｉｖ感染の治療への使用におけるシクロスポリン誘導体
US8143244B2 (en) *	2009-02-26	2012-03-27	Bristol-Myers Squibb Company	Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
CA2801517C (en)	2010-06-24	2017-12-12	Janssen R&D Ireland	Preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7h-indolo-[2,1-.alpha.]-[2]-benzazepine-10-carboxylic acid
US20120196794A1 (en)	2010-08-06	2012-08-02	Bristol-Myers Squibb Company	Combinations of Hepatitis C Virus Inhibitors
EP2655362A1 (en)	2010-12-22	2013-10-30	Abbvie Inc.	Hepatitis c inhibitors and uses thereof
MX2013007677A (es)	2010-12-30	2013-07-30	Abbvie Inc	Inhibidores macrociclicos de serina proteasa de hepatitis.
US8951964B2 (en)	2010-12-30	2015-02-10	Abbvie Inc.	Phenanthridine macrocyclic hepatitis C serine protease inhibitors
US10201584B1 (en)	2011-05-17	2019-02-12	Abbvie Inc.	Compositions and methods for treating HCV
US8716275B2 (en) *	2011-10-20	2014-05-06	Bristol-Myers Squibb Company	Compound for the treatment of hepatitis C
SG11201500157TA (en) *	2012-07-18	2015-03-30	Bristol Myers Squibbholdings Ireland	Novel methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3-methoxy-5a-((1 r,5s) -3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide
WO2015103490A1 (en)	2014-01-03	2015-07-09	Abbvie, Inc.	Solid antiviral dosage forms
US12083099B2 (en)	2020-10-28	2024-09-10	Accencio LLC	Methods of treating symptoms of coronavirus infection with viral protease inhibitors
US12274700B1 (en)	2020-10-30	2025-04-15	Accencio LLC	Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US752354A (en) *		1904-02-16		Composition post
US753137A (en) *		1904-02-23		Dust-pan
US756203A (en) *	1903-11-14	1904-04-05	Oliver E Barthel	Muffler.
PT1719773E (pt)	2004-02-24	2009-06-03	Japan Tobacco Inc	Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv
US7348425B2 (en) *	2004-08-09	2008-03-25	Bristol-Myers Squibb Company	Inhibitors of HCV replication
US7153848B2 (en) *	2004-08-09	2006-12-26	Bristol-Myers Squibb Company	Inhibitors of HCV replication
DE502005002697D1 (de)	2004-10-13	2008-03-13	Merck Patent Gmbh	Als kinaseinhibitoren geeignete derivate des n,n'-diphenylharnstoffs
US7662809B2 (en)	2004-10-26	2010-02-16	Istituto Di Richerche Di Biologia Molecolare P Angeletti Spa	Tetracyclic indole derivatives as antiviral agents
GB0518390D0 (en)	2005-09-09	2005-10-19	Angeletti P Ist Richerche Bio	Therapeutic compounds
US7399758B2 (en) *	2005-09-12	2008-07-15	Meanwell Nicholas A	Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) *	2005-09-13	2009-01-06	Bristol-Myers Squibb Company	Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) *	2006-02-08	2008-11-25	Bristol-Myers Squibb Company	HCV NS5B inhibitors
GB0608928D0 (en) *	2006-05-08	2006-06-14	Angeletti P Ist Richerche Bio	Therapeutic agents

2007
- 2007-05-03 US US11/743,921 patent/US7456166B2/en not_active Expired - Fee Related
- 2007-05-04 KR KR1020087027866A patent/KR101417145B1/ko not_active Expired - Fee Related
- 2007-05-04 NZ NZ572555A patent/NZ572555A/en unknown
- 2007-05-04 CA CA2651690A patent/CA2651690C/en not_active Expired - Fee Related
- 2007-05-04 JP JP2009511151A patent/JP5284952B2/ja active Active
- 2007-05-04 PL PL07761873T patent/PL2024375T3/pl unknown
- 2007-05-04 WO PCT/US2007/068209 patent/WO2007136982A1/en not_active Ceased
- 2007-05-04 DK DK07761873.4T patent/DK2024375T3/da active
- 2007-05-04 SI SI200730612T patent/SI2024375T1/sl unknown
- 2007-05-04 BR BRPI0711821-0A patent/BRPI0711821A2/pt not_active IP Right Cessation
- 2007-05-04 DE DE602007013036T patent/DE602007013036D1/de active Active
- 2007-05-04 AU AU2007253998A patent/AU2007253998B2/en not_active Ceased
- 2007-05-04 EA EA200802346A patent/EA015286B1/ru not_active IP Right Cessation
- 2007-05-04 HR HR20110194T patent/HRP20110194T1/hr unknown
- 2007-05-04 MX MX2008014435A patent/MX2008014435A/es active IP Right Grant
- 2007-05-04 EP EP07761873A patent/EP2024375B1/en active Active
- 2007-05-04 AT AT07761873T patent/ATE501156T1/de active
- 2007-05-15 PE PE2007000585A patent/PE20080070A1/es active IP Right Grant
- 2007-05-17 AR ARP070102138A patent/AR061008A1/es active IP Right Grant
- 2007-05-17 TW TW096117512A patent/TWI401244B/zh not_active IP Right Cessation
2008
- 2008-10-30 IL IL195025A patent/IL195025A/en not_active IP Right Cessation
- 2008-11-04 NO NO20084637A patent/NO341663B1/no not_active IP Right Cessation
- 2008-11-07 ZA ZA2008/09548A patent/ZA200809548B/en unknown
2011
- 2011-06-03 CY CY20111100539T patent/CY1111526T1/el unknown

Also Published As

Publication number	Publication date
JP5284952B2 (ja)	2013-09-11
PL2024375T3 (pl)	2011-07-29
PE20080070A1 (es)	2008-03-10
NO20084637L (no)	2008-12-15
US7456166B2 (en)	2008-11-25
CA2651690C (en)	2014-11-04
BRPI0711821A2 (pt)	2012-01-17
AU2007253998B2 (en)	2012-03-15
KR101417145B1 (ko)	2014-07-08
EP2024375A1 (en)	2009-02-18
HRP20110194T1 (hr)	2011-04-30
ATE501156T1 (de)	2011-03-15
NO341663B1 (no)	2017-12-18
WO2007136982A1 (en)	2007-11-29
US20070270405A1 (en)	2007-11-22
NZ572555A (en)	2010-11-26
EA200802346A1 (ru)	2009-06-30
IL195025A0 (en)	2009-08-03
TW200804282A (en)	2008-01-16
AR061008A1 (es)	2008-07-30
JP2009537557A (ja)	2009-10-29
HK1122814A1 (en)	2009-05-29
MX2008014435A (es)	2008-11-27
DK2024375T3 (da)	2011-06-27
CY1111526T1 (el)	2016-02-10
IL195025A (en)	2013-09-30
EA015286B1 (ru)	2011-06-30
EP2024375B1 (en)	2011-03-09
TWI401244B (zh)	2013-07-11
ZA200809548B (en)	2009-12-30
CA2651690A1 (en)	2007-11-29
KR20090008344A (ko)	2009-01-21
DE602007013036D1 (de)	2011-04-21
AU2007253998A1 (en)	2007-11-29

Publication	Publication Date	Title
IL195025A0 (en)	2009-08-03	Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
IL198401A0 (en)	2010-02-17	Hcv ns3 protease inhibitors
EP1906945A4 (en)	2009-07-15	HCV INHIBITORS
IL197907A0 (en)	2009-12-24	Hcv nucleoside inhibitor
HRP20160410T8 (hr)	2019-04-19	Inhibitori hepatitis c virusa
IL233818A0 (en)	2014-09-30	Inhibitors to ns5a hcv
ZA201104911B (en)	2012-03-28	Inhibitors of hcv ns5a
ZA201008988B (en)	2012-01-25	Hcv protease inhibitors
IL195515A0 (en)	2011-08-01	Macrocyclic oximyl hepatitis c protease inhibitors
EP2410841A4 (en)	2012-10-24	SUBSTITUTED BICYCLIC HCV INHIBITORS
SI2094702T1 (sl)	2016-03-31	Virusni inhibitorji
EP2432318A4 (en)	2012-11-21	NS3 PROTEASE INHIBITORS OF BIPACROCYCLIC HEPATITIS C VIRUS
GB2439606B (en)	2011-08-17	An oscillator
ZA200902475B (en)	2010-03-31	HCV NS3 Protease Inhibitors
ZA200711069B (en)	2009-03-25	HCV inhibitors
ZA200903379B (en)	2010-07-28	Hepatitis C virus inhibitors
GB0611451D0 (en)	2006-07-19	Cellular antagonist
HUS1500008I1 (hu)	2016-10-28	Hepatitis C vírus inhibitorok
AU313340S (en)	2007-03-20	Chiller bottle
AU313339S (en)	2007-03-20	Chiller bottle
ZA200903014B (en)	2010-07-28	Hepatitis C virus inhibitors
ZA200810235B (en)	2009-10-28	Macrocyclic oximyl hepatitis C protease inhibitors